Perihilar Cholangiocarcinoma
Conditions
Keywords
perihilar cholangiocarcinoma, ERCP, Radiofrequency ablation
Brief summary
This prospective clinical trial aims to assess the feasibility, efficacy, and safety of a personalized radiofrequency ablation protocol coupled with complete biliary drainage for patients presenting with inoperable perihilar cholangiocarcinoma.
Detailed description
This clinical trial proposes a personalized treatment approach to inoperable perihilar cholangiocarcinoma consisting of endoluminal ablative therapy via radiofrequency ablation followed by endoscopic biliary drainage. Patients presenting with jaundice / biliary obstruction caused by inoperable perihilar cholangiocarcinoma as assessed during multidisciplinary case discussion will be invited to enroll in this trial. Patients will be randomized in a 1:1 fashion to receive biliary plastic stenting (control arm) or biliary plastic stenting + radiofrequency ablation via endoscopic approach. In cases where ERCP fails to achieve adequate biliary drainage, stenting and/or drainage will be attempted via percutaneous approach. Additional systemic chemotherapy will be offered to all eligible patients according to the local standard of care. Patients will be followed up with a clinical visit at 2 weeks and stent exchange (+ additional RFA treatment in the control arm) will be offered at 8-12 weeks interval until disease progression, clinical deterioration precluding ERCP or death. The main study objectives are: * To assess the technical feasibility of implementing the proposed therapeutic protocol involving a combined endoscopic-radiologic approach to drainage and ablation * To evaluate the efficacy of radiofrequency ablation in local disease control * To evaluate whether complete drainage and radiofrequency ablation have a cumulative benefit in patients with inoperable perihilar cholangiocarcinoma * To evaluate the safety of our proposed therapeutic protocol combining interventional endoscopy with radiology
Interventions
PROCEDUREEndoluminal radiofrequency ablation
Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
PROCEDUREEndoscopic biliary stenting
Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
Sponsors
Clinical Hospital Colentina
Carol Davila University of Medicine and Pharmacy
Universitatea din Bucuresti
Asociatia pentru cercetare si educatie in gastroenterologie (ACEG)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* perihilar cholangiocarcinoma * locally advanced disease (unresectable) * M1 (limted to 1 site)
Exclusion criteria
* refusal to sogn the ICF * poor performance status (ECOG \>2) * surgically altered anatomy (i.e Bilroth II or Roux-en-Y interventions) * significant comorbidities * ASA score \>3 * life expectancy \<3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Technical success of ERCP procedure | 2 months | Ability to correctly apply radiofrequency ablation and place stents in all the biliary ducts accessed on ERCP |
| Tumor response | 6 months | To evaluate the efficacy of radiofrequency ablation in local disease control by assessing tumor response according to RECIST criteria at 6 months follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of procedure-related adverse events | 12 months | To evaluate the safety profile of the procedure by assessing the rate of procedure-related adverse events according to the ASGE lexicon (cholangitis, bleeding, perforation, pancreatitis) after endoscopic treatment |
| Overall survival | 12 months | To assess patient survival rates at 12 months follow-up |
| Tumor microenvironment alterations | 2 months | To evaluate the expression of programmed death (PD)-1 / PD- ligand 1 markers on biopsy samples of tumor tissue obtained at the index and follow-up ERCP procedure |
Countries
Romania
Outcome results
None listed